Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Perioperativ andningsvård och resultat för patienter som genomgår högriskbukkirurgi (PENGUIN)

11 november 2026 uppdaterad av: University of Birmingham

PERioperativ andningsvård och resultat för patienter som genomgår högriskabdominal kirurgi: en 2x2 faktoriell, internationell pragmatisk randomiserad kontrollerad studie i låg- och medelinkomstländer

PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.

Patients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.

Studieöversikt

Detaljerad beskrivning

PENGUIN is a pragmatic, blinded (outcome assessor), 2x2 factorial, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce surgical site infection (SSI) and pneumonia rates in patients undergoing surgery with an abdominal incision.

Pneumonia is one of the most serious complications to occur after surgery, accounting for up to one in four of all postoperative deaths. The incidence is greater still in high-risk populations such as those undergoing midline laparotomy where mortality rates are more than 10%. SSIs are clearly important being the most frequent healthcare-associated infection in LMICs, affecting one in three patients undergoing contaminated or dirty surgery (34, 35). SSIs cause pain, discomfort and disability. They increase the time taken to return to work, and healthcare costs

The risk of postoperative mortality and complications such as surgical site infection is three times greater in low and middle-income countries (LMICs) than in high-income countries. In order to address surgical need worldwide, it is estimated that provision of a further 312 million operations would be required each year.

Patients will be recruited from hospitals in Low and Middle Income Countries (LMICs) who are undergoing elective or emergency mid-line laparotomy. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between:

A. Preoperative chlorhexidine mouthwash and 80-100% FiO2 during surgery B. No preoperative chlorhexidine mouthwash and 80-100% FiO2 during surgery C. Preoperative chlorhexidine mouthwash and 21-30% FiO2 during surgery D. No preoperative chlorhexidine mouthwash and 21-30% FiO2 during surgery

The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main Randomised Control Trial will recruit 12,924 participants.

Studietyp

Interventionell

Inskrivning (Faktisk)

11668

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Porto Alegre, Brasilien
        • Hospital de Clinicas de Porto Alegre
      • Porto Alegre, Brasilien
        • Hospital Nossa Senhora da Conceicao
      • Salvador, Brasilien
        • Hospital Universitario Professor Edgar Santos/Bahia
      • São José, Brasilien
        • Hospital Sao Jose - Criciuma/SC
    • São Paulo
      • Botucatu, São Paulo, Brasilien
        • Hospital das Clinicas da Faculdade de Medicina de Botucatu - UNESP
      • Bhubaneswar, Indien, 751019
        • All India Institute of Medical Sciences, Bhubaneswar
      • Chandigarh, Indien, 160047
        • Government Medial College & Hospital, Chandigarh
      • Jodhpur, Indien, 342005
        • All India Institute of Medical Sciences, Jodhpur
      • Kolkata, Indien, 700160
        • Tata Medical Center
      • Ludhiana, Indien, 141008
        • Christian Medical College (CMC) & Hospital, Ludhiana
      • Madhepura, Indien, 852113
        • Madhepura Christian Hospital
      • Mumbai, Indien, 400012
        • Tata Memorial Hospital
      • Mumbai, Indien, 400008
        • Topiwala National Medical College and Bai Yamunabai Laxman Nair Charitable Hospital
      • New Delhi, Indien, 110002
        • Maulana Azad Medical College
      • Rishikesh, Indien, 249203
        • All India Institute of Medical Sciences, Rishikesh
      • Vellore, Indien, 632004
        • Christian Medical College & Hospital Vellore
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, Indien, 530053
        • Homi Bhabha Cancer Hospital & Research Centre
    • Jammu and Kashmir
      • Srinagar, Jammu and Kashmir, Indien, 190011
        • Sher - i - Kashmir Institute of Medical Sciences
    • Maharashtra
      • Chinchpāda, Maharashtra, Indien, 425417
        • Chinchpada Christian Hospital
    • Manipal, Karnataka
      • Madhava Nagar, Manipal, Karnataka, Indien, 576104
        • Kasturba Medical College Hospital, Manipal
    • Punjab
      • Patiāla, Punjab, Indien, 147001
        • Government Medical College, Patiala
      • Belisario Domínguez, Mexiko, 44329
        • Centro Médico Nacional de Occidente IMSS
      • Veracruz, Mexiko, 91700
        • Hospital Espanola Veracruz
      • Benin City, Nigeria, 300283
        • University of Benin Teaching Hospital
      • Gwagwalada, Nigeria, 902101
        • University Of Abuja Teaching Hospital
      • Ibadan, Nigeria, 200285
        • University College Hospital
      • Ile-Ife, Nigeria, 233285
        • Obafemi Awolowo University Teaching Hospitals Complex
      • Ilorin, Nigeria, 241102
        • University of Ilorin Teaching Hospital
      • Kaduna, Nigeria, 810105
        • Ahmadu Bello University Teaching Hospital
      • Kano, Nigeria, 700101
        • Aminu Kano Teaching Hospital
      • Lagos, Nigeria, 102215
        • Lagos University Teaching Hospital
      • Lagos, Nigeria, 101233
        • Lagos State University Teaching Hospital
      • Nnewi, Nigeria, 435101
        • Nnamdi Azikiwe University Teaching Hospital
      • Kigali, Rwanda
        • University Teaching Hospital Kigali
      • Cape Town, Sydafrika, 7505
        • Tygerberg Hospital
      • Cape Town, Sydafrika, 7925
        • Groote Schuur Hospital
      • Cape Town, Sydafrika, 8001
        • New Somerset Hospital
      • Paarl, Sydafrika, 7646
        • Paarl Provincial Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

10 år till 100 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults and children aged 10 years or over
  • Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length
  • Written informed consent of patient (signature or a fingerprint)

Exclusion Criteria:

  • Patients undergoing caesarean section
  • Patients with a documented or suspected allergy to chlorhexidine
  • Patient unable to complete postoperative follow-up (not contactable after discharge)
  • Previous enrolment in PENGUIN within the past 30 days
  • American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Faktoriell uppgift
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Mouthwash and liberal oxygen during surgery

Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.

0.2% Chlorhexidine digluconate

Oxygen 80-100%

Oxygen 21-30 %

Aktiv komparator: No mouthwash and liberal oxygen during surgery

No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.

Oxygen 80-100%

Oxygen 21-30 %

Experimentell: Mouthwash and restrictive oxygen during surgery

Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.

0.2% Chlorhexidine digluconate

Oxygen 80-100%

Oxygen 21-30 %

Aktiv komparator: No mouthwash and restrictive oxygen during surgery

No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.

Oxygen 80-100%

Oxygen 21-30 %

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with pneumonia using the US Centers for Disease Control (CDC) definition of pneumonia (Mouthwash intervention only)
Tidsram: Within 30 days post-surgery from index operation

Pneumonia will be classified using the US Centers for Disease Control (CDC) definition of pneumonia

Within 30 days post-surgery from index operation
Number of participants with surgical site infection (Oxygen therapy intervention only)
Tidsram: Within 30 days post-surgery from index operation

The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision AND The patient must have at least one of the following:

  • Purulent drainage from the wound
  • Organisms are detected from a wound swab
  • Wound opened spontaneously or by a clinician AND, fever (>38°C), OR at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat;
  • Diagnosis of SSI by a clinician or radiological imaging
Within 30 days post-surgery from index operation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of trial participant moralities (Mouthwash and oxygen therapy intervention comparisons)
Tidsram: Within 30 days post-surgery from index operation

Patient mortality status

Within 30 days post-surgery from index operation
Number of participants who received repeat abdominal surgery to treat complications (Oxygen therapy intervention only)
Tidsram: Within 30 days post-surgery from index operation

Repeat abdominal surgery to treat complications

Within 30 days post-surgery from index operation
Number of participants who received repeat abdominal surgery (Mouthwash and oxygen therapy interventions)
Tidsram: Within 30 days post-surgery from index operation

Repeat abdominal surgery

Within 30 days post-surgery from index operation
Length of hospital stay for index admission (Mouthwash and oxygen therapy interventions)
Tidsram: Within 30-days post surgery from index operation

Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.

Within 30-days post surgery from index operation
Number of participants returning to normal activities (Mouthwash and oxygen therapy interventions)
Tidsram: Within 30 days post-surgery from index operation

Return to normal activities (e.g. work, school, or family duties) ascertained by trial specific case report forms.

Within 30 days post-surgery from index operation
Number of participants admissions to a critical care unit (Mouthwash and oxygen therapy interventions)
Tidsram: Within 30 days post-surgery from index operation

Admission to a critical care unit will be captured on the trial case report forms.

Within 30 days post-surgery from index operation
Health resource usage per patient
Tidsram: Within 30 days post-surgery from index operation

Resource use data will be collected as part of the economic evaluation of the different treatment combinations in a sub-group of adult patients at selected centers.

Information related to post-operative cost (medicinal products, amenities and personal) will be collected on a health resource usage case report form designed by the trials health economist.

Within 30 days post-surgery from index operation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Rupert Pearse, Royal London Hospital

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 november 2020

Primärt slutförande (Faktisk)

19 augusti 2026

Avslutad studie (Faktisk)

30 september 2026

Studieregistreringsdatum

Först inskickad

31 januari 2020

Först inskickad som uppfyllde QC-kriterierna

4 februari 2020

Första postat (Faktisk)

5 februari 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Data will be shared via a process of controlled access

Tidsram för IPD-delning

6 months post publication

Kriterier för IPD Sharing Access

Formal requests must be submitted to the Data Access Group at Birmingham Clinical Trials Unit

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera